HYBIO(SZ:300199)2022-12-07 08:18Group 1: Fundraising and Investment Plans - The company has approved a non-public offering of shares, pending shareholder approval and submission to the China Securities Regulatory Commission [2] - Funds raised will enhance R&D capabilities, focusing on innovation in drug formulation and delivery methods to strengthen industry position [2] - The funds will also support the "Internet + Chronic Disease Management Platform" and marketing network construction, aiming to expand product promotion and establish a data-driven service platform for chronic disease patients [3] Group 2: R&D Investment and Strategy - The company maintains an annual R&D investment ratio of approximately 10% of sales revenue, positioning itself as a leader in the peptide drug sector [3] - Ongoing efforts include enhancing R&D capabilities, protecting intellectual property, and increasing product development for domestic and international markets [3] - The company is in the early stages of large-scale product launches, with expectations for continued increases in R&D investment [3] Group 3: Product Development and Collaborations - The clinical trials for a non-invasive continuous glucose monitoring device in collaboration with Pudi Medical are progressing well, with EU certification expected by November [3] - Following EU certification, the company plans to apply for market access in Hong Kong and Macau, and will seek approval from the National Medical Products Administration in China [3]